Skip to main content

Advertisement

Table 1 Randomized, double-blind, placebo-controlled trials of SLIT performed since 2009

From: Sublingual immunotherapy: World Allergy Organization position paper 2013 update

Author, year [reference] Ages (y) A/P Dropouts (A/P) Allergen Duration Dose and administration Disease Manu-facturer Main positive results Negative results
Horak, 2009 [43] 18-50 45/44 3/4 Grass 4 mo 20 mcg RC STA Significant reduction in RC score in Vienna challenge chamber at 4 mo in SLIT vs baseline and vs placebo (the reduction vs placebo was 29%) Nasal airflow
Phl p 5/day Weight of secretions
Tablets Basophil activation
Increased IgE and IgG4
Skoner, 2010 [46] 18-50 39 med 4 Ragweed 6 mo 4.8 or 48 mcg RC GRE Combined symptoms+drugs and drug score versus placebo Nasal challenge, IgE
36 high 5    Amb a 1/day Symptom score
40 plac 3    Metered pump during peak season
Cortellini, 2010 [42] 16-44 15/12 0/1 Alternaria 10 mo 60 mcg Alt a 1 cumul. 6 mcg/mo RCA ANA Significant reduction in combined score (-38% versus placebo). Specifcic IgE and IgG4
Drops    Significant reduction in skin reactivity
Panizo, 2010 [45] 18-65 52/26 2/1 Grass 5 mo 25 mcg Phl p 5/day Tablets RC ALK Increase in IgE, IgG4, and IgE blocking activity only in active  
Yonekura, 2010 [48] 7-15 20/11 1/2 Mite 1 y 0.5 mcg Der f 1 once a week RC TOR Significant decrease in symptoms and combined score in wk 0–3 and 37–40 only in SLIT Medication score
Blaiss, 2011 [40] 5-17 349/358 33/30 Grass 6 mo 450 g Phl p 5/mo RC STA Significant reduction in combined score (-26%) versus placebo. Quality of Life 38% improvement vs placebo Asthma symptoms
Nelson, 2011 [44] 18-63 213/225 33/33 Grass 10 mo 450 mcg Phl p 5/mo Tablets RCA STA Significant reduction in combined score (-20%and medication score (-20%) versus placebo Daily medication score
Bush, 2011 [41] 18-50 High 10 2 Mite 18 mo 70 or 1 mcg RA GRE Significant reduction in specific bronchial reactivity Symptoms and medication scores
Low 10 3 (Der f) Der f 1 per dose.
Pla 11 5 Drops
Increase in IgG4
Stelmach, 2012 [47] 6-18 Cont 20 3 Grass 2 y Cumulative 7.3 and 3.6 mcg Phl p 5. Drops RCA ALK Significant improvement in drugs +symptoms with both continuous and precoseasonal regimen. Reduction in FeNO Symptom score
Prec 20 1 Medication score
Pla 20 2 Pulmonary function
de Bot, 2012 [53] 6-18 126/125 15/17 Mite 2 y 4.06 mcg RC ART   Symptom score
Der p 1/week QoL
Drops Medication score
Well days
Ahmadiasfshar 2012 [49] 5-18 12/12 2/2 Grass 6 mo Cumulative: about 6,000 IR Spray RC STA Significant improvement in symptom and medication scores  
Reduction of skin wheal diameter
Wahn, 2012 [54] 4-12 158/49 26/2 Grass 8 mo Cumulative: 7.2–8.4 mg group 5 RC ALL Significant reduction versus placebo in combined symptom/medication and individual scores  
Drops
Cox, 2012 [51] 18-65 233/240 26/17 Grass 6 mo Cumulative: approx 3.6 mg group 5 allergen. RC STA Significant reduction of combined symptom + medication score (-28% versus placebo) and overall quality of life Itchy nose symptom score versus placebo
Tablets
Bozek, 2013 [50] 60-75 51/57 7/9 Mite 3 y NS RC STA Total nasal scores decreased by 44% from baseline in SLIT and by 6% in placebo. Symptoms after specific nasal provocation versus placebo
Medication score decreased 35% from baseline in SLIT group.
Wang, 2013 [55] 4-65 60/60 12/23 Mite 6 mo NS RC ZHE Significant decrease in each individual rhinitis symptom versus placebo starting from week 14. No change versus placebo in medication intake
Nolte, 2013 [18] 18-50 High 187 142 Ragweed 1 y 6 or 12 mcg RCA MSD Significant decrease in combined symptom + medication score for both active groups VS placebo (21% and 27%)  
Low 190 overall Amb a 1 daily
Pla 188 Tablets
Creticos, 2013 [52] 18-50 Low 197 40 Ragweed 1 y Cumulative dose RCA MSD Only the high dose decreased daily symptom, medication, and combined scores during peak pollen season and whole season versus placebo. Low dose overall less effective than the 2 other doses on symptoms/medications in peak pollen and whole season
Med 195 43 4.38 mg Amb a 1
High 194 57 Tablets
   Pla 198 38        
  1. Abbreviations: A/P active/placebo, NS not stated, RC rhinoconjunctivitis, RCA rhinoconjuntivitis/asthma, STA Stallergenes, GRE Greer, ANA Anallergo, ALL Allergopharma, ALK ALK-Abellò, MSD Merck Sharp and Dome, TOR Torii Pharmaceuticals, ZHE Zheng Wolwo Bio Pharma.